| Up
2005P-0237:
Re-Listing Petition to Determine that Two Strenghths, 50 mg and
250 mg Lamotrigene Oral Tablets, were not Withdrawn Due to Safety
nor Efficacy Concerns
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
|
| CP1
|
| 06/15/2005
|
| 06/15/2005
|
| Private Industry
|
| Pharmaceutical Patent
Attorneys, LLC
|
|
|
|
|
|
|
| Table
of Contents
|
|
|
|
|
| Signature:
|
| Mark Pohl, Esq.
|
|
|
|
|
| ACK1
|
| 06/16/2005
|
| 06/16/2005
|
| Federal
Government
|
| HFA-305
to Pharmaceutical Patent Attorneys, LLC
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
|
|
|
|
|
|
| Signature:
|
| Lyle D. Jaffe
|
|
|
| LET1
|
| 12/15/2005
|
| 12/15/2005
|
| Federal
Government
|
| HFD-005
to Pharmaceutical Patent Attorneys, LLC
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
|
|
|
|
|
|
| Signature:
|
| Jane A. Axelrad
| |
Top | Up
Page last updated
January 3, 2006
kk
Dockets Home Page | Dockets
Contacts and Location | Operating
Status | Item
Code Definitions | Federal
Register
FDA Home Page | Search
FDA Site | FDA A-Z Index
| Contact FDA
FDA/Dockets Management |
